ImmunityBio Reports Strong ANKTIVA Sales Growth and Secures First Global NSCLC Approval with Subcutaneous Administration

summarizeSummary

ImmunityBio announced robust preliminary Q4 and full-year 2025 product revenue, driven by ANKTIVA sales, alongside a landmark Saudi FDA approval for ANKTIVA in non-small cell lung cancer, marking its first global approval for this indication and subcutaneous use.

check_boxKey Events

• Record ANKTIVA Revenue Growth

  Preliminary net product revenue for FY2025 reached approximately $113.0 million, a 700% increase year-over-year, with Q4 2025 revenue at $38.3 million, up 20% quarter-over-quarter.

• Landmark NSCLC Approval

  The Saudi FDA granted approval of ANKTIVA in combination with immune checkpoint inhibitors for metastatic non-small cell lung cancer, representing the first global approval for this indication and the first for subcutaneous administration.

• Expanded NMIBC Approval

  The SFDA also approved ANKTIVA in combination with BCG for BCG-unresponsive non-muscle invasive bladder cancer carcinoma in situ, adding to existing approvals in the U.S. and U.K.

• Strong Cash Position

  The company ended Q4 2025 with an estimated $242.8 million in cash, cash equivalents, and marketable securities.

auto_awesomeAnalysis

This 8-K filing signals significant positive momentum for ImmunityBio, driven by both strong commercial execution and key regulatory advancements. The substantial year-over-year and quarter-over-quarter revenue growth for ANKTIVA demonstrates increasing market adoption and commercial success. Crucially, the Saudi FDA's approval of ANKTIVA for non-small cell lung cancer, particularly as the first global approval for this indication and for subcutaneous administration, opens a new, potentially large market and enhances the drug's versatility and patient convenience. This approval validates the broader applicability of ImmunityBio's platform beyond bladder cancer. The solid cash position further supports ongoing development and commercialization efforts, reducing near-term financing concerns. Investors should monitor the continued commercial ramp-up of ANKTIVA and the progress of the NSCLC launch, as well as further regulatory expansions.